Travere Therapeutics, Inc. cash flow to debt ratio of 11.49% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Travere Therapeutics, Inc.'s free cash flow has increased -93.98% from $-338.69M last year to $-20.37M, signaling increasing performance

Travere Therapeutics, Inc.'s debt to equity ratio is 3.32, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

Travere Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 6.80 last year to 3.32 today, signaling strengthened financials

Travere Therapeutics, Inc. has a net debt to EBITDA ratio of 10.61x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

Travere Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Travere Therapeutics, Inc.'s profit margin has increased (-97.10%) in the last year from -137.90% to -4.00%, signaling increasing performance

Travere Therapeutics, Inc.'s short-term assets of $437.56M exceed its short-term liabilities of $159.90M

Travere Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Travere Therapeutics, Inc.'s return on equity of -26.79%, is lower than 15.00%, indicating bad performance

Travere Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Travere Therapeutics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Travere Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Travere Therapeutics, Inc. has negative free cash flow, indicating cash burn

Travere Therapeutics, Inc.'s yearly earnings has increased -92.06% since last year from $-321.55M to $-25.55M, signaling increasing performance

Travere Therapeutics, Inc.'s yearly revenue has increased 110.45% since last year from $233.18M to $490.73M, signaling increasing performance

ROIC -13.09% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Travere Therapeutics, Inc.'s 3-year revenue CAGR of 64.89% is positive, indicating growing revenue over the past 3 years

Travere Therapeutics, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Travere Therapeutics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Travere Therapeutics, Inc. has insufficient data to evaluate this check.

Travere Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Travere Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Travere Therapeutics, Inc. has an EV/EBITDA ratio of 249.43x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Travere Therapeutics, Inc. is overvalued relative to its fair value price of -161.05 based on Earnings Fair Value model

Travere Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Travere Therapeutics, Inc. has a price-to-book ratio of 53.09x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Travere Therapeutics, Inc. has a price-to-sales ratio of 9.78x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue